



Complement Therapeutics Appoints Dr Muhammad Ali Memon FRCOphth, as Chief Medical Officer

Munich, Germany – 26th November 2024 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Muhammad Ali Memon as its Chief Medical Officer, effective 1st January 2025.

Dr. Memon is a qualified ophthalmologist and joins CTx from AAVantgarde Bio, where he held the position of Vice President, Clinical Science and Safety. Prior to AAVantgarde, Dr. Memon has held various roles including Clinical Director at Novai as well being an honorary consultant at Moorfields Eye Hospital in London.

Dr. Memon received his medical degree from Aga Khan University, prior to his research fellowship at Harvard University. He then joined the Royal College of Ophthalmologists for his Ophthalmology Residency Program.

"We are excited to welcome Ali to the CTx team as Chief Medical Officer" said **Dr Rafiq Hasan, Chief Executive Officer**. "Ali's extensive clinical experience and expertise in ophthalmic clinical development will be critical as we prepare to bring our lead asset CTx001, into the clinic. We are excited to have him join us in advancing our vision to develop the next generation of complement therapies."

"I am thrilled to join CTx in developing treatments for the underserved and rapidly growing population with age-related macular degeneration. CTx001, a single-dose gene therapy, holds the potential to reshape Geographic Atrophy treatment by targeting the complement system. Encouraging preclinical findings demonstrate substantial modulation of the complement pathway, providing hope to millions of GA patients who currently have few therapeutic options." said **Dr Muhammad Ali Memon, Chief Medical Officer**. "With this novel approach, CTx001 could significantly impact the GA treatment landscape and enhance the quality of life for those living with this challenging condition."

About Complement Therapeutics GmbH:

Complement Therapeutics GmbH (CTx) is a German headquartered early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.

Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for Geographic Atrophy, a leading cause of blindness. Additional programs will evaluate potential therapeutic opportunities in other complement-mediated conditions.

The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable the quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.

The Company has subsidiaries in the UK (Complement Therapeutics Ltd) and in the USA (Complement Therapeutics Inc) as well as research laboratories in Stevenage, UK.

--Ends--

For more information please visit: <https://complementtx.com/>

Company Contact

Dr Rafiq Hasan, CEO and Managing Director

Complement Therapeutics GmbH

Email: info@complementtx.com